Roundview Capital’s Boston Scientific BSX Stock Holding History

Roundview Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,003	Closed	-$668K	–	341
2025 Q4	$668K	Buy	7,003 +2,026	+41%	+$199K	0.04%	228
2025 Q3	$486K	Sell	4,977 -82	-2%	-$8.49K	0.03%	265
2025 Q2	$543K	Buy	5,059 +2,980	+143%	+$302K	0.04%	256
2025 Q1	$210K	Buy	+2,079	New	+$209K	0.02%	309

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Roundview Capital's BSX Position: Q1 2026 in Review

Roundview Capital sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 7,003 shares — an estimated $668K sold.

Roundview Capital first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $668K in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Roundview Capital reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Roundview Capital sold 7,003 Boston Scientific shares in Q1 2026, an estimated $668K.
Roundview Capital first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
Roundview Capital's Boston Scientific position peaked at $668K in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Roundview Capital's 13F filing for Q1 2026, filed 8 May 2026.